RAD-140, sold as testolone, is a non-steroidal selective androgen receptor modulator (SARM). Of the compounds people take to build muscle, it is the one most often described as the strongest and, at the same time, the one with the least controlled human data behind it. That combination — high potency, low evidence — is the single most important thing to understand about it. This guide covers what it is, what has actually been measured, and where the genuine warning signs are.
Testolone was first developed as a candidate drug, including work exploring it in hormone-driven breast cancer. It never became an approved medicine. Everything sold under the name today comes from the unregulated research-chemical market, which matters a great deal once you reach the safety section.
How it works
Like other muscle-targeting SARMs, RAD-140 is a small non-steroidal molecule that binds the androgen receptor and switches it on. The design goal for the class is tissue selectivity: strong activation in muscle and bone, weaker activation in tissues like the prostate. In preclinical models RAD-140 does show anabolic activity, and it is generally described as one of the more potent binders in the group. Potency is not a benefit on its own — a stronger androgen signal also means stronger downstream consequences, including suppression.
What the human data shows (and does not)
There is very little. Unlike ostarine, which has completed phase 2 trials, testolone has no published dosing studies in healthy people measuring body composition or hormones at the doses users actually take. Its human exposure comes mainly from an early oncology program and from scattered clinical case reports. That means the confident claims you see about exact lean-mass gains are not backed by controlled trials in healthy lifters — they are extrapolation from potency and from user anecdote.
- No phase 2 body-composition trials in healthy adults.
- No controlled hormone-axis data at recreational doses.
- The recreational doses people report are well above anything formally tested.
So the honest position is that RAD-140 is expected to be anabolic based on its mechanism and animal data, but the size and reliability of that effect in people is not established by the kind of evidence that exists for ostarine or even ligandrol.
Realistic effects
Users generally report firm strength and lean-mass gains and describe it as more aggressive than ostarine or ligandrol, alongside a stimulant-like edge and, sometimes, irritability or poor sleep. These are self-reports, not trial endpoints, and they are exactly the kind of claim that mislabelled products make unreliable — if the bottle does not contain what it says, the reported effect is not attributable to RAD-140 at all.
Suppression and PCT considerations
As a potent androgen receptor agonist, RAD-140 is read by the body as an androgen. The brain responds by turning down the signalling hormones (LH and FSH) that drive natural testosterone production, so the testes make less of their own. In plain terms: it suppresses you. Because it sits at the potent end of the class, the expectation — supported by the bloodwork users share — is that suppression is on the heavier side rather than trivial.
What that implies:
- Recovery of natural production may be slow or incomplete after longer or stacked use. Some people rebound on their own after short exposure; others do not bounce back cleanly.
- The standard tools used to restart the axis are selective estrogen receptor modulators (SERMs) such as tamoxifen or clomifene, the same drugs used after a steroid cycle. They nudge the brain to release more LH and FSH.
- There are no controlled trials of PCT specifically in RAD-140 users, so exactly who needs a SERM, at what dose, and for how long is not established. The only way to know your own response is bloodwork before, during, and after. SERMs are prescription drugs with their own side effects, not supplements.
Safety signals: the liver problem
The standout red flag for RAD-140 is a cluster of published case reports of drug-induced liver injury in people taking products sold as testolone. Several describe significant hepatocellular injury — jaundice, markedly raised liver enzymes — appearing weeks into use, with some cases severe. This is the clearest documented safety signal of any of the popular muscle SARMs.
An important caveat runs both ways. Because these products come from an unregulated market, it is not always possible to prove the injury was caused by RAD-140 itself rather than a contaminant or a substituted compound. That uncertainty is not reassuring — it is the point. When you cannot verify what is in the bottle, you cannot cleanly separate the drug's risk from the market's risk, and both land on the person taking it.
The grey-market problem
RAD-140 is not a licensed medicine, so nothing about its manufacture is quality-controlled. Independent testing of products marketed as SARMs has repeatedly found bottles containing the wrong compound, no active ingredient, an unlisted extra drug, or an anabolic steroid substituted in, with doses far off the label. For a compound whose main safety signal is liver injury, that unreliability compounds the hazard: you may not be taking RAD-140 at all, or not at the stated dose. Athletes should also note SARMs are banned by WADA in and out of competition, and contaminated products have caused failed tests.
Bottom line
RAD-140 is the most potent and least human-tested of the headline muscle SARMs. It is expected to be anabolic and is expected to suppress natural testosterone, but neither is backed by controlled trials at real-world doses. Its distinguishing feature is not a proven benefit — it is a documented safety signal, the liver-injury case reports, made harder to interpret by an unregulated supply chain. Long-term human data does not exist. Treat any confident claim about it, good or bad, as under-evidenced. This is reference information, not medical advice.